Dezacot
Generic Name
Deflazacort
Manufacturer
Leading Pharmaceutical Company
Country
Global/Various
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| dezacot 30 mg tablet | ৳ 32.00 | ৳ 320.00 |
Description
Overview of the medicine
Dezacot 30 mg Tablet contains Deflazacort, which is a corticosteroid used for its anti-inflammatory and immunosuppressant properties. It is prescribed for a wide range of conditions including severe allergic reactions, asthma, rheumatic disorders, skin disorders, and certain kidney diseases.
Uses & Indications
Dosage
Adults
Dosage varies significantly based on the condition being treated and patient response. Typically ranges from 6 mg to 90 mg orally once daily, initially. Dosing for Duchenne muscular dystrophy is approximately 0.9 mg/kg/day.
Elderly
No specific dose adjustment is generally required, but caution is advised due to increased susceptibility to side effects and potential age-related decline in renal or hepatic function.
Renal_impairment
No specific dose adjustment is typically required for mild to moderate renal impairment. However, use with caution and monitor for side effects.
How to Take
Take orally, with or without food. It can be taken once daily, preferably in the morning to align with the body's natural corticosteroid rhythm.
Mechanism of Action
Deflazacort is an inactive prodrug that is rapidly converted to its active metabolite, 21-desacetyl deflazacort. This active metabolite binds to glucocorticoid receptors in the cytoplasm, leading to a complex series of events that modify gene expression. This results in the inhibition of various inflammatory mediators and cells, thereby exerting its potent anti-inflammatory and immunosuppressive effects.
Pharmacokinetics
Onset
Anti-inflammatory effects typically begin within hours of administration. Full therapeutic effects may take days to weeks depending on the condition.
Excretion
Primarily excreted in the urine (approximately 70%) and feces (approximately 30%) as various metabolites, with less than 5% as unchanged drug.
Half life
The elimination half-life of the active metabolite (21-desacetyl deflazacort) is approximately 1.1 to 1.9 hours.
Absorption
Rapidly absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations of the active metabolite are reached within 1-2 hours.
Metabolism
Extensively metabolized in the liver to the active metabolite 21-desacetyl deflazacort, primarily via CYP3A4. This active metabolite is further metabolized.
Side Effects
Contraindications
- •Systemic fungal infections
- •Known hypersensitivity to deflazacort or any components of the formulation
- •Administration of live or live-attenuated vaccines during therapy
Drug Interactions
NSAIDs
Concurrent use may increase the risk of gastrointestinal ulcers and bleeding.
Oral Hypoglycemics and Insulin
May reduce the hypoglycemic effect; increased monitoring of blood glucose levels may be required.
Anticoagulants (e.g., Warfarin)
May alter the anticoagulant effect; close monitoring of INR/PT is recommended.
Diuretics (e.g., Thiazides, Loop Diuretics)
May enhance the potassium-depleting effect, increasing the risk of hypokalemia.
CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)
May increase plasma concentrations of deflazacort's active metabolite, potentially leading to increased side effects. Dose adjustment may be necessary.
CYP3A4 Inducers (e.g., Rifampicin, Phenytoin, Carbamazepine)
May decrease plasma concentrations of deflazacort's active metabolite, potentially reducing its efficacy. Dose adjustment may be necessary.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose may include exaggerated side effects such as fluid retention, high blood pressure, and severe mood changes. Treatment is symptomatic and supportive. There is no specific antidote for deflazacort overdose.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Deflazacort is excreted in breast milk; therefore, caution should be exercised when administered to a nursing mother. Consult a doctor.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, consult the specific packaging for details.
Availability
Pharmacies, hospitals
Approval Status
Approved in many countries
Patent Status
Generic available
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
